Status | Topic selection |
Technology type | Medicine |
Decision | Not selected |
Further information | Decision makers have concluded that the clear rationale to not evaluate your product is due to a clinical guideline (CG150) being available that already which includes a recommendation for the use of combination therapy with an oral triptan and an NSAID for the acute treatment of migraine. Therefore, a TA would not add any further value. |
ID number | 12055 |
Project Team
Project lead | Danielle Lees |
Email enquiries
- If you have any queries please email topic.selection@nice.org.uk
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
10 September 2024 | Topic selection |
For further information on how we select topics for development, please see our page about prioritising our guidance topics